IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Pediatric High-grade Glioma (HGG)

NCT ID: NCT06946680

Last Updated: 2026-01-08

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-03-18
• Study Completion Date: 2045-12-31

Brief Summary

This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ pediatric high-grade glioma

Detailed Description

Identified newly-diagnosed pediatric CD70+ HGG patients will be enrolled in this clinical trial study prior to initiation of standard-of-care chemo-radiation. Prior to initiation of chemoradiation, PBMCs will be collected through peripheral venipuncture. After tumor CD70 status is confirmed, the 8R-70CAR T cell production will start.

4 weeks (+/- 1) post completion of radiation, pediatric patients, based on institutional policy, will initiate adjuvant chemo with dose-intensified TMZ 75-100 mg/m2/day x 21 days for up to 3 cycles. 8R-70CAR T cells will be administered at day 21-24 of the TMZ cycle as a single intravenous (IV) infusion, or for pediatric patients not receiving adjuvant chemo once 8R-70CAR T cells. Pediatric patients will receive lymphodepletion prior to CAR T cell administration.

Conditions

High-grade Glioma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

8R-70CAR T cells

Cohort 1 will receive 1 x 10\^6 cells/kg. Cohort 2 will receive 1 x 10\^7 cells/kg. Cohort 3 will receive 1 x 10\^8 cells/kg.

Group Type: EXPERIMENTAL

Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells

Intervention Type: BIOLOGICAL

Single dose of 8R-70CAR T cells administered IV

Interventions

Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells

Single dose of 8R-70CAR T cells administered IV

Intervention Type: BIOLOGICAL

Other Intervention Names

8R-70CAR T cells

Eligibility Criteria

Inclusion Criteria

• Newly-diagnosed pHGG based on the absence of a previous history of brain tumor (WHO Grade III-IV glioma) by histopathology.
• CD70 positive (≥5%, 1+) The tumors from the surgical resection or biopsy by immunohistochemistry will be confirmed by a validated assay performed at UF Health Pathology, a certified Lab.

o CD70 tumor expression performed on paraffin-embedded tumor specimens will be evaluated. Tumor expression will be scored on a scale of 0 to 3 staining intensity: 0 = Negative

1. = Low level

2. = Moderate level

3. = High level The criteria for inclusion will be at least 5% of the cells scoring 1+ staining intensity (> 5%, 1+).

• Karnofsky Performance Status (KPS) or Lansky Performance Score (LPS) of > 70% Patients who are unable to walk because of neurologic deficits, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score provided the neurological deficit is stable.
• CBC with differential with adequate bone marrow function as defined below:

• Absolute neutrophil count (ANC) ≥ 1000 cells/mm3.
• Platelet count ≥ 100,000 cells/mm3.
• Hemoglobin ≥ 10 g/dl. (The use of transfusion or other intervention to achieve Hgb ≥ 10 g/dl is acceptable.)
• Adequate renal function as defined below:

o Serum creatinine < 1.5 x institutional upper limit of normal for age and gender. Patients who do not meet the criteria but have a 24-hour Creatinine Clearance or GFR (radioisotope or iothalamate) ≥ 70 mL/min/1.73 m2 are eligible

• Adequate hepatic function as defined below:

• Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) for age
• ALT ≤ 3 times institutional upper limits of normal for age
• AST ≤ 3 times institutional upper limits of normal for age
• Signed informed consent, or for patients age <18, parental permission, and, as appropriate, assent from pediatric patients age ≥12. If the patient's mental status precludes their informed consent, the legally authorized representative may give informed consent. Consent or permission/assent will be obtained at screening (before PBMC collection) and before treatment with CAR T-cells.
• For females of childbearing potential, a negative serum pregnancy test at enrollment.
• Women of childbearing potential (WOCBP) must be willing to use an acceptable contraceptive method to avoid pregnancy throughout the study and for at least 24 weeks after the last dose of study drug.
• Males with female partners of childbearing potential must agree to practice adequate contraceptive methods throughout the study and should avoid conceiving children for 24 weeks following the last dose of study drug.

Exclusion Criteria

• Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free for ≥ 3years. (In situ cancer is permissible)
• Spinal metastasis and leptomeningeal involvement.
• Patients with Bulky Tumors:

• 3 cm in a single dimension (post-surgery)
• Tumor causing uncal herniation or mass effect leading to midline shift with or without symptoms or signs of impending herniation or
• Obstruction to CSF flow
• Recurrent or multifocal malignant gliomas.
• The patient is not a candidate for cellular therapy as assessed by the study bone marrow transplant physician.
• Known immunosuppressive disease or human immunodeficiency virus (HIV) infection.

HIV-positive patients are ineligible due to the unknown safety and efficacy of infusing these patients with CAR T cells genetically modified using retroviral vectors. Additionally, the immunosuppression used for treatment in this study will pose an unacceptable risk.

• Concurrent illness: Patients with active autoimmune disease, documented history of autoimmune disease/syndrome, or any other condition that requires ongoing systemic steroids or systemic immunosuppressive agents, except

• Patients with vitiligo or resolved asthma/atopy
• Patients with hypothyroidism stable on hormone replacement or Sjogren's syndrome
• Patients requiring physiologic doses of corticosteroids (up to 0.5 mg/m2/day dexamethasone equivalent)

• History of or ongoing pneumonitis or significant interstitial lung disease.
• Ongoing or active uncontrolled infection.
• Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that in the opinion of the investigator, would compromise the patient's ability to tolerate protocol therapy, put them at additional risk for toxicity or would interfere with the study procedures or results.
• Patients with any of the following cardiac diseases:
• New York Heart Association (NYHA) functional class III or IV
• Clinically significant cardiac arrhythmia including, but not limited to, Torsade de pointes or requiring a pacemaker
• Left ventricular ejection fraction below 50% as determined by echocardiography (ECHO)

• Pregnant or lactating women, due to possible adverse effects on the developing fetus or infant.
• Patients treated on any other therapeutic clinical protocols within 30 days prior to enrollment.
• For females of childbearing potential, a negative serum pregnancy test at enrollment.

• Minimum Eligible Age: 4 Years
• Maximum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Florida Department of Health, Live Like Bella

UNKNOWN

Sponsor Role: collaborator

St. Baldrick's Foundation

OTHER

Sponsor Role: collaborator

American Brain Tumor Association

OTHER

Sponsor Role: collaborator

University of Florida

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ashley Ghiaseddin, MD

Role: PRINCIPAL_INVESTIGATOR

University of Florida

Locations

University of Florida Health Children's Hospital

Gainesville, Florida, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Marcia Hodik, RN, BSHS

Role: CONTACT

wells-BTC@ufl.edu

352-273-5519

Facility Contacts

Marcia Hodik, RN, BSHS

Role: primary

wells-BTC@ufl.edu

352-273-5519

Other Identifiers

OCR41673

Identifier Type: OTHER

Identifier Source: secondary_id

IRB202200057-P

Identifier Type: -

Identifier Source: org_study_id